Quanome Agrees to Invest in AI Drug Discovery Company QAI Labs

Insider Brief

• Quanome Technologies has agreed to acquire an approximately 5% stake in QAI Labs through an all-stock transaction, in exchange for newly issued Quanome shares representing approximately 15.97% of its post-transaction outstanding stock.
• The investment supports Quanome’s Quantum Life Sciences strategy and gives it an interest in QAI Labs’ NOVA-3 platform, which combines AI-based antibody candidate selection, quantum algorithms run on classical simulators, and laboratory testing.
• QAI Labs remains at an early, pre-commercial stage, with its antibody candidates requiring laboratory validation, clinical development, and regulatory approval before potential commercialisation.

PRESS RELEASE — Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) today announced that it has entered into a definitive agreement, dated November 4, 2026, for its strategic investment in QAI Labs Ltd. (“QAI Labs” or “QAI”), an early-stage life sciences technology company developing NOVA-3, an AI-enabled discovery platform designed to combine quantum-computing algorithms (run on classical simulators) with laboratory testing to advance multi-specific antibody candidates. Under the all-stock transaction, QAI Labs will issue at closing 31,579 new shares to Quanome, representing approximately 5% equity interest in QAI Labs immediately after the issuance. In exchange, Quanome will issue at closing 6,541,236 new shares of its common stock to QAI Labs, equal to approximately 19% of Quanome’s outstanding common stock immediately before the issuance, and approximately 15.97% immediately after the issuance. Closing is subject to customary closing conditions.

The proposed investment may advance Quanome’s Quantum Life Sciences – Molecular Discovery stream, one of the Company’s four targeted strategic pillars for applying quantum science and artificial intelligence to high-value industry challenges. QAI Labs brings together a digital discovery platform, a quantum-computing algorithm program (run on classical simulators) and laboratory research capability in Sugar Land, Texas.

QAI Labs’ NOVA-3 platform is designed to use AI to assemble and rank multi-specific antibody candidates before laboratory work begins. According to information provided by QAI, its curated library includes antibody building-block pairs, which may support the evaluation of a broad range of potential molecular combinations. Its research program is exploring how quantum-enhanced methods may assist selected complex calculations and optimization problems, with laboratory results designed to feed back into each new molecule design cycle. This integrated loop is intended to help prioritize candidates for laboratory evaluation and improve the allocation of research resources. QAI Labs remains at an early, pre-commercial stage, with all molecule candidates require laboratory validation, clinical development and regulatory approval before potential commercialization.

“This investment agreement puts another of Quanome’s quantum and AI strategy streams into execution,” said Yang Li, Chief Executive Officer of Quanome Technologies. “QAI Labs is building a more focused engine for early-stage molecular discovery: using advanced computing to identify promising multi-specific antibody candidates sooner, then validating the strongest designs in the laboratory. The platform aims to improve the pace and precision of molecule discovery and help create better treatment options for patients. We believe this may represent a compelling long-term opportunity for us.”

“Our objective is to use AI to identify and rank promising designs, test where quantum-enhanced approaches can add value to difficult calculations, and validate the selected outputs in the laboratory,” said Dr. Daniel Feng, Co-Founder of QAI Labs. “Quanome’s investment provides strategic backing to accelerate the evaluation and continued development of NOVA-3, further expanding the platform’s scientific and partnership potential.”

Drug discovery begins with an immense field of possible molecules and a high rate of failure. AI and quantum-enabled methods have the potential to compress design cycles, sharpen candidate selection and direct laboratory resources toward the molecules that are worth creating and testing. They do not replace clinical trials or regulatory review, but they can create a more disciplined route from digital design to laboratory validation – and a faster opportunity to potentially support more patients in medical treatments.

Quanome intends to support QAI Labs’ development through its investment, strategic engagement and relevant relationships across its Scientific Advisory Network and broader ecosystem. The Company will seek opportunities to strengthen scientific review, technical capability, validation pathways and complementary life-sciences partnerships as QAI Labs develops its platform. Following closing, the parties intend to pursue a strategic collaboration in AI-driven drug discovery. QAI Labs continues to operate independently and is not a subsidiary of Quanome.

As part of its investment review, Quanome considered a third-party valuation report and other relevant factors in evaluating the transaction. The parties assigned the consideration shares an aggregate negotiated transaction value of US$5.0 million, corresponding to an implied equity valuation of approximately US$100 million for QAI Labs based on the equity interest acquired. The Quanome shares to be issued in the transaction will not be registered under the Securities Act of 1933, as amended, and will be subject to applicable transfer restrictions.